Corifact Market Report 2026

Corifact Market Overview

• The Corifact market growth in the historic period has been driven by recognition of fibrinogen deficiency, trauma care advancements • Market expansion is supported by growth in emergency surgeries, aging population needs • Growth Driver: Rising Prevalence Of Bleeding Disorders Driving Growth In The Corifact Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Corifact Market?

Corifact refers to a fibrinogen concentrate used in medical treatments to manage bleeding, particularly in patients with fibrinogen deficiency or low fibrinogen levels, which can occur in conditions such as trauma, surgery, or liver disease. Corifact helps to promote blood clotting by providing fibrinogen, a protein essential for the formation of blood clots. The main types of products in corifact are human-derived factor XIII and recombinant factor XIII. Human-derived Factor XIII (FXIII) refers to a protein involved in the final stages of blood clotting. The various therapeutic applications include routine prophylactic treatment and perioperative management. It is distributed through hospital pharmacies, specialty pharmacies, and outpatient clinics.

What Is The Corifact Market Growth Forecast?

The growth in the forecast period can be attributed to growth in emergency surgeries, aging population needs, trauma center expansion, improved coagulation diagnostics, demand for rapid hemostatic agents. Major trends in the forecast period include increased use of fibrinogen concentrates, focus on rapid bleeding control, expansion of trauma and surgical care, hospital based hemostasis management, rising adoption in liver disease treatment.

Global Corifact Market Segmentation

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII 2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management 3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

What Are The Drivers Of The Corifact Market?

The increasing prevalence of bleeding disorders is expected to propel the growth of the corifact market going forward. Bleeding disorders are conditions that impair the blood's ability to clot properly, leading to excessive or prolonged bleeding. The rise in bleeding disorders can be attributed to improved diagnosis, increased awareness, advances in genetic testing, as well as lifestyle changes and the prevalence of underlying conditions. Corifact treats bleeding disorders caused by factor XIII deficiency by replacing the missing clotting factor, helping form stable blood clots, and reducing excessive bleeding. For instance, in December 2023, according to the report published by the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO), a UK-based organization, 2023/24 indicates the burden of bleeding disorders, with 6,835 individuals recorded with haemophilia A, 1,378 with haemophilia B, alongside 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Therefore, the increasing prevalence of bleeding disorders is driving the growth of the corifact industry. Rise in demand for biological products is expected to propel the growth of the corifract market going forward. Biological products refer to complex pharmaceutical substances derived from living organisms, used to diagnose, prevent, treat, and cure diseases and medical conditions. The rise in demand for biological products are attributed to growing environmental concerns, heightened consumer awareness, and the need for sustainable and effective alternatives to synthetic chemicals. Corifract supports biological products by enhancing their stability, bioavailability, and efficacy, ensuring optimal performance and prolonged shelf life through innovative formulation and delivery solutions. For instance, in August 2025, according to the Assistant Secretary for Planning and Evaluation, a US-based government department, net revenue for biosimilars can span from a USD 33.5 million loss in smaller markets to USD 9.5 billion in larger ones, and proposed regulatory changes including universal interchangeability, a global comparator, and removal of comparative efficacy studies are estimated to cut development costs and raise lifetime revenues by USD 2 billion, USD 13.5 million, and USD 84 million, respectively. Therefore, the rise in demand for biological products drives the corifract market. An increasing number of surgical procedures is expected to propel the growth of the corifact market going forward. Surgical procedures refer to medical operations performed by healthcare professionals to treat injuries, diseases, or abnormalities through manual or instrumental methods. The rise in surgical procedures is primarily due to an aging population requiring treatment for age-related conditions and advancements in minimally invasive technologies, which make surgeries safer and more accessible. Corifact is used in surgical procedures to prevent and control excessive bleeding in patients with congenital Factor XIII deficiency by stabilizing blood clots and supporting wound healing. For instance, in June 2024, according to the American Society of Plastic Surgeons, a US-based specialty organization, a 7 percent growth in minimally invasive procedures in 2023 surpassed surgical procedures by 2 percent, with neuromodulator injections and hyaluronic acid fillers each exceeding 9 million and 5 million treatments, respectively. Therefore, the increasing number of surgical procedures is driving the growth of the corifact industry.

Key Players In The Global Corifact Market

Major companies operating in the corifact market are CSL Behring

Regional Insights

North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Corifact Market?

The corifact market consists of sales of products including fibrinogen concentrates, factor concentrates, coagulation factor products, cryoprecipitate, and recombinant clotting factors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Corifact Market Report 2026?

The corifact market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the corifact industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.